Ernexa Therapeutics Inc.: share-based compensation expense

What this measure means

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Exact concept: us-gaap:ShareBasedCompensation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2010-01-01 to 2025-12-31. The SEC response was captured on 2026-09-19.

Selected filing history

Related financial histories

• Ernexa Therapeutics Inc.: total assets
• Ernexa Therapeutics Inc.: total liabilities
• Ernexa Therapeutics Inc.: stockholders equity
• Ernexa Therapeutics Inc.: cash and cash equivalents
• Ernexa Therapeutics Inc.: net income or loss
• Ernexa Therapeutics Inc.: operating cash flow
• Ernexa Therapeutics Inc.: capital expenditure payments
• Ernexa Therapeutics Inc.: revenue
• Ernexa Therapeutics Inc.: contract revenue excluding tax
• Ernexa Therapeutics Inc.: financing cash flow
• Ernexa Therapeutics Inc.: investing cash flow
• Ernexa Therapeutics Inc.: retained earnings or deficit
• Ernexa Therapeutics Inc.: basic weighted-average shares
• Ernexa Therapeutics Inc.: diluted weighted-average shares
• Ernexa Therapeutics Inc.: basic earnings per share
• Ernexa Therapeutics Inc.: diluted earnings per share
• Ernexa Therapeutics Inc.: income tax expense or benefit
• Ernexa Therapeutics Inc.: net property, plant and equipment
• Ernexa Therapeutics Inc.: operating income or loss
• Ernexa Therapeutics Inc.: current assets
• Ernexa Therapeutics Inc.: interest expense
• Ernexa Therapeutics Inc.: current liabilities
• Ernexa Therapeutics Inc.: current accounts payable
• Ernexa Therapeutics Inc.: goodwill carrying amount
• Ernexa Therapeutics Inc.: net finite-lived intangible assets
• Ernexa Therapeutics Inc.: net current accounts receivable
• Ernexa Therapeutics Inc.: operating expenses
• Ernexa Therapeutics Inc.: gross profit
• Ernexa Therapeutics Inc.: cost of revenue
• Ernexa Therapeutics Inc.: selling, general and administrative expense
• Ernexa Therapeutics Inc.: research and development expense

Inspect the source

Entity

Ernexa Therapeutics Inc. / CIK 0000748592

Captured

2026-09-19T15:01:44.435Z

SEC response SHA-256

c12754d65dfa742127976ccd7c75bc4379d46dc7b617393cfbda0b7763329d5c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000748592.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))